Protecting and shredding paper in reality is just a false sense of security

Protecting and shredding paper, in reality, is just a false sense of security.Focus needs to come off the paper and be directed at the source of the document.Unless it was handwritten, the document was generated electronically and in 99%of cases the data still resides on a hard drive or other media. The Dow unit will collaborate with wheat breeding firm World Wide WheatLLC of Phoenix, Ariz., to develop and commercialize advanced germplasm andgenetic traits in wheat. YorkSenior Manager, Marketing PRTel: +1-240-686-7660Email: Copyright 2009, Market Wire, All rights reserved.-0-. QIAGENemploys more than 3,100 people in over 30 locations worldwide. Furtherinformation about QIAGEN can be found at http:// contained in this release that are not historical facts areforward-looking statements, including statements about our products,markets, strategy and operating results. This panel includes the digene HPV Test, which is regarded asthe “gold standard” in testing for high-risk types of humanpapillomavirus (HPV), the primary cause of cervical cancer.

QIAGEN’s assay technologies includeone of the broadest panels of molecular diagnostic tests availableworldwide. The companyprovides its products to molecular diagnostics laboratories, academicresearchers, pharmaceutical and biotechnology companies, and appliedtesting customers for purposes such as forensics, animal or food testingand pharmaceutical process control. The demand existsfor a robust, fast, sensitive method to detect activating mutations of theKRAS gene in clinical samples.About QIAGEN:QIAGEN N.V., a Netherlands holding company, is the leading global providerof sample and assay technologies. Sample technologies are used to isolateand process DNA, RNA and proteins from biological samples such as blood ortissue. Assay technologies are used to make such isolated biomoleculesvisible. QIAGEN has developed and markets more than 500 consumableproducts as well as automated solutions for such consumables. Studies haveshown that KRAS mutation testing can better define which CRC patients willbenefit from treatment with epidermal growth factor receptor (EGFR)inhibiting monoclonal antibodies, such as Amgen’s Vectibix (panitumumab)and Imclone/Bristol-Myers Squibb/Merck KgaA’s Erbitux (cetuximab).Established clinical guidelines describe treatment of metastasized coloncancer for patients with the unmutated KRAS gene only.

Mutant KRAS is present inapproximately 35-45 % of metastatic colorectal cancers (CRC). Mutations in the KRAS gene result in a KRAS protein that ispermanently active. Such oncogenic activation has been suggested to beinvolved in many aspects of the development and progression of cancer,including abnormal cell growth, proliferation, and differentiation, aswell as increased invasion and metastasis. Mutations in the RAS family of proto-oncogenes (comprised of HRAS,NRAS and KRAS) are very common, being found in up to 30 % of all humantumors. For assay detection, such solutionsinclude QIAGEN’s PyroMark systems for quantitative sequence-based typingof known and unknown mutations as well as the Rotor-Gene(R) Q for HRM(TM)mutation screening and multiplex real-time PCR analysis.About KRAS and personalized medicine:KRAS is an oncogene which plays a crucial role in the development oftumors. QIAGEN also produces and markets CE-IVDmarked solutions for genomic DNA preparation from tissue and bloodincluding the EZ1 Advanced Diagnostic Sample Technology instrument forhigh quality rapid purification of up to 12 samples in less than 25minutes. The assay itself produces reliable results for 12 samples injust 20 minutes.

These platforms are widely established and recognized asthe solution of choice for clinical sample preparations in manylaboratories worldwide.Currently, researchers are already widely using QIAGEN solutions in thepursuit of personalized medicine. The kit contains primers and controls forreal-time, sequence-based detection and quantification of mutations in theKRAS codons 12, 13, and 61. The kit is compliant with EU IVD Directive98/79/EC, enabling detection and quantification of mutations of the KRASgene for in vitro diagnostics. “Therefore, we plan to use this technology to furtherexpand our portfolio of regulated assays for mutation profiling in cancertreatments. Based upon a complete chain of CE-marked sample preparationand detection technologies such as the PyroMark Q24 MDx instrument, weaim to provide our customers a broad menu of regulated assays enabling theadaptation of more effective and efficient cancer therapies.”In addition to mutation profiling, QIAGEN is committed to the developmentof other assays for research use for analyzing expression profiles andmethylation markers in signaling pathways targeted by cancer therapeutics.QIAGEN is active in several collaborations and partnerships withresearchers and pharmaceutical companies advancing the new model ofpersonalized medicine.QIAGEN’s PyroMark KRAS Kit was validated on the bench top CE-IVD compliantPyroMark Q24 MDx system. It thereby offers significant advantages overother technologies such as PCR, making it the premier choice for companiondiagnostic assays which trigger the further evolution of personalizedcancer treatment,” commented Thomas Schweins, Vice President Marketing andStrategy at QIAGEN. The study has uncovered high numbers of previouslyunknown mutations in codons of the KRAS gene not routinely covered byPCR-based tests.”Pyrosequencing is a unique technology allowing detection andquantification of both known and unknown genetic mutations occurring inshort stretches of genes.